Craig-Hallum says data presented at the American College of Medical Genetics and Genomics Annual Meeting that shows a significant reduction in healthcare resource utilization and total healthcare cost for patients who receive a GeneDx (WGS) whole exome or genome test could support improved commercial and Medicaid coverage for GeneDx’s whole exome and genome tests. The firm keeps a Buy rating and $153 price target on shares of GeneDx, which are down $7.88, or 9%, to $77.22 this morning after competitor Natera (NTRA) announced the commercial launch of Zenith genomics, the company’s whole genome sequencing assay designed to improve the detection of rare diseases.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Natera announces commercial launch of Zenith genomics
- GeneDx falls after Natera launches sequencing assay for rare diseases
- CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF
- Genedx Earnings Call Signals Strong Genomics Growth
- 3 Best Growth Stocks to Buy Now, According to Analysts – 3/9/2026